)
Hyderabad-based biopharmaceutical company, Suven Life Sciences today said it has secured patents in the US and New Zealand.
The patents relate to its new chemical entities (NCE) for central nerves system therapy. These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, the company said.
The patents are valid until 2030 and 2031 respectively.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,"said Venkat Jasti, CEO of Suven.
The company has "secured patents in USA and New Zealand to one of their new chemical entity (NCE) for CNS therapy through new mechanism of action - H3 Inverse agonist...," Suven Life Sciences said.
With these new patents, Suven has a total of 20 granted patents from US and 23 granted patents from New Zealand.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
"Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," Suven said.
Meanwhile, Suven Life Sciences shares were trading 4.95% up at Rs 261 apiece on the BSE.
